Henry Schein, Inc. HSIC
Composite 49/100; the shares have moved about 23% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 38/100 — a slight mark against it.
Momentum ranks 72/100 — a moderate point in its favour.
Quality ranks 38/100 — a slight mark against it. Growth ranks 44/100 — a slight mark against it. Valuation ranks 48/100 — a slight mark against it.
What the company does Henry Schein distributes dental and medical supplies, equipment, and technology to practitioners worldwide across three segments: Global Distribution, Specialty Products, and Technology. It also offers branded consumables, implants, biomaterials, and digital solutions, including equipment repair and financial services.
Key financials Revenue growth 6.3%, EPS growth 4.5%. Margins: gross 31.2%, operating 5.9%, net 2.9%. ROE 8.8%, ROA 4.4%, ROCE 8.7%. Debt/Equity 0.81, net debt/EBITDA 3.39, interest coverage 4.53. Forward P/E 16.05, PEG 0.26, EV/EBITDA 13.65.
Stock health Sideravia overall score 47.4 (Weak quality, fairly valued, positive momentum). Quality 34.3, Momentum 71.4. Piotroski F-Score 5/9, Altman Z 2.82. RSI(14) 61.00, 3m momentum 21.80%.
Price vs fair value The stock trades at a **discount of 8.00%** versus the analyst mean target of 95.31. - Q2 2026 earnings beat and raised guidance sparked bullish coverage (Zacks, Simply Wall St., MarketBeat). - Recent articles debate valuation after a 37% run and fresh 52-week highs (Zacks, Simply Wall St.). - Analysts highlight strong Q2 metrics and stock climb post-earnings (Zacks).
Looking forward Forward P/E 16.05 and PEG 0.26 suggest undemanding valuation relative to growth. Momentum remains positive but RSI nears neutral. Execution on specialty products and digital integration will be key for margin expansion and multiple re-rating.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.